Analysis of topoisomerase mutations in fluoroquinolone-resistant and -susceptible Campylobacter jejuni strains isolated in Senegal.
In this study, topoisomerase mutations in ciprofloxacin-resistant and -susceptible Campylobacter jejuni were analysed by DNA sequencing. In certain ciprofloxacin-resistant C. jejuni, the mechanism of resistance was complex. The Thr86-Ala substitution in the GyrA protein appears to play a role in increasing the minimum inhibitory concentration of nalidixic acid only. In addition, isolates with this amino acid change and those resistant to quinolones but lacking a mutation in the GyrA quinolone resistance-determining region could be derived from two different clones. Based on gyrA and gyrB polymorphisms, C. jejuni isolates from the Dakar region of Senegal appeared to be less diverse than those from other countries. Moreover, C. jejuni isolates in Senegal appeared to differ from European isolates by lack of a silent mutation at codon 120 of the gyrA gene.
Kinana
Alfred Dieudonné
AD
Laboratoire de Biologie Médicale, Institut Pasteur de Dakar, Senegal. kinana@pasteur.sn
Cardinale
Eric
E
Bahsoun
Ibrahim
I
Tall
Fatou
F
Sire
Jean-Marie
JM
Garin
Benoit
B
Boye
Cheikh Saad-Bouh
CS
Dromigny
Jacques-Albert
JA
Perrier-Gros-Claude
Jean-David
JD
D000818:Animals; D002169:Campylobacter Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D016123:Campylobacter jejuni / Q000187:drug effects* / Q000235:genetics*; D027081:DNA Gyrase / Q000187:drug effects / Q000235:genetics*; D027101:DNA Topoisomerase IV / Q000187:drug effects / Q000235:genetics; D024881:Drug Resistance, Bacterial / Q000235:genetics*; D005060:Europe; D024841:Fluoroquinolones / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D009154:Mutation; D009268:Nalidixic Acid / Q000494:pharmacology; D011110:Polymorphism, Genetic; D012675:Senegal / Q000453:epidemiology
D024841:Fluoroquinolones; D009268:Nalidixic Acid; D027101:DNA Topoisomerase IV; D027081:DNA Gyrase